| 非致残性缺血性脑血管事件药物治疗进展 |
| |
| 引用本文： | 李振华,刘著,胡全忠.非致残性缺血性脑血管事件药物治疗进展[J].中国卒中杂志,2022,17(4):407-412. |
| |
| 作者姓名： | 李振华 刘著 胡全忠 |
| |
| 作者单位： | 1 西宁 810000青海大学研究生院2 青海省人民医院神经内科 |
| |
| 基金项目： | 青海省科学技术厅项目（2019-ZJ-7051）
|
| |
| 摘 要： | 非致残性缺血性脑血管事件(non-disabling ischemic cerebrovascular events,NICE)占缺血性脑血管病的50％～60％.近年来,NICE的治疗从最初的单药抗血小板到双联抗血小板取得了重大突破,研究证明21?d的短程、双联抗血小板方案具有更高的有效性和安全性.NICE患者进行溶栓...
|
| 关 键 词： | 非致残性缺血性脑血管事件 缺血性卒中 短暂性脑缺血发作 阿司匹林 氯吡格雷 抗血小板治疗 溶栓 |
| 收稿时间： | 2021-12-26 |
Progress in Drugs Therapy for Non-disabling Ischemic Cerebrovascular Events |
| |
| LI Zhenhua,LIU Zhu,HU Quanzhong.Progress in Drugs Therapy for Non-disabling Ischemic Cerebrovascular Events[J].Chinese Journal of Stroke,2022,17(4):407-412. |
| |
| Authors: | LI Zhenhua LIU Zhu HU Quanzhong |
| |
| Abstract: | The non-disabling ischemic cerebrovascular events (NICE) accounted for 50%-
60% of ischemic cerebrovascular diseases. In recent years, the treatment of NICE has made a
major breakthrough from the initial mono anti-platelet therapy to double anti-platelet therapy
(DAPT), and the previous studies suggested that the short-course DAPT for 21 days had higher
efficacy and safety. Intravenous thrombolysis for NICE can increase the risk of bleeding, so it is
still controversial whether NICE patients should receive thrombolysis. The NICE type, NIHSS
score, thrombolysis time window and drug dose are influencing factors for thrombolysis. For NICE
patients carrying CYP2C19 LOF gene, ticagrelor has better therapeutic effect than clopidogrel. In
addition, polymorphism of other genes also has an impact on the prognosis of NICE. The research
on gene polymorphism may become a new direction for stroke treatment in the future. |
| |
| Keywords: | Non-disabling ischemic cerebrovascular event Ischemic stroke Transient ischemic attack Aspirin Clopidogrel Antiplatelet therapy Thrombolysis
|
|
| 点击此处可从《中国卒中杂志》浏览原始摘要信息 |
| 点击此处可从《中国卒中杂志》下载免费的PDF全文 |
